Hanmi Pharm Co.

Hwaseong, South Korea

Hanmi Pharm Co.

Hwaseong, South Korea
SEARCH FILTERS
Time filter
Source Type

A tenofovir disoproxil phosphate, and a pharmaceutical composition including tenofovir disoproxil phosphate or a pharmaceutically acceptable salt thereof, a non-metallic salt disintegrant, and a non-metallic salt lubricant are provided.


The present invention provides an amorphous solid dispersion comprising a taxane or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which has enhanced solubility. Also provided is a method for preparing the solid dispersion. The present invention also provides a tablet having good solubility, bioavailability and stability, which comprises the amorphous solid dispersion, an intragranular excipient, and an extragranular excipient.


Provided are a composite preparation and a method for producing same, the composite preparation comprising a core containing a first active ingredient; and a film coating layer containing a 5--reductase inhibitor, wherein the film coating layer is formed by coating with a film coating solution in which the film coating materials are dissolved in a mixed solvent of water and about 30-80 wt% of an organic solvent with respect to a total weight of the mixed solvent.


Patent
Hanmi Pharm. Co. and Hanmi Science Co. | Date: 2017-03-15

The present invention relates to a thienopyrimidine derivative of generic formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.


The present invention relates to a method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment, in which the method comprises conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment; and a composition for improving the solubility of a physiologically active protein or peptide, comprising an immunoglobulin Fc fragment, in which the composition improves the solubility compared to a composition without an immunoglobulin Fc fragment..


Patent
Hanmi Pharm. Co. | Date: 2017-04-12

The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.


The present invention relates to a composition for preventing or treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist, and a method for preventing or treating diabetes mellitus. More specifically, the present composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate according to the present invention can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker.


The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.


Provided are a composite preparation and a method for producing same, the composite preparation comprising a core containing a first active ingredient; and a film coating layer containing a second active ingredient, wherein the film coating layer comprises a polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol.


The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide analogue conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.

Loading Hanmi Pharm Co. collaborators
Loading Hanmi Pharm Co. collaborators